Platelet aggregation inhibiting compounds
    7.
    发明授权
    Platelet aggregation inhibiting compounds 失效
    血小板聚集抑制化合物

    公开(公告)号:US6028087A

    公开(公告)日:2000-02-22

    申请号:US10238

    申请日:1998-01-21

    摘要: Compounds of the formula (I):W--Z--(CR'R.sup.10).sub.r --U--(CR'.sub.2).sub.s --V--A (I)wherein:A is ##STR1## W is .sup.N ; Z is (CH.sub.2).sub.1-2 ;U and V independently are present as CO, CR'.sub.2, C(.dbd.CR'.sub.2), S(O).sub.r, O, NR', CR'OR', CR'(OR")CR'.sub.2, CR'.sub.2 CR'(OR"), C(O)CR'.sub.2, CR'.sub.2 C(O), CONR', NR'CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR', NR'C(S), S(O).sub.r NR', NR'S(O).sub.r, N.dbd.N, NR'NR', NR'CR'.sub.2, NR'CR'.sub.2, CR'.sub.2 O, OCR'.sub.2, C.tbd.C, CR'.dbd.CR', or CR'(NR'R")C(O);each r independently is 0 to 3;s is 0 to 2;each R' independently is H, C.sub.1-4 alkyl, C.sub.3-7 cycloalky-C.sub.0-4 alkyl, or Ar-C.sub.0-4 alkyl;each R" independently is R', --C(O)R', or --C(O)OR.sup.15 ;R.sup.10 is H, C.sub.1-4 alkyl, or --NR'R';each R.sup.15 independently is C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-4 alkyl, or Ar-C.sub.0-4 alkyl;R.sup.2 is present once or twice as C.sub.1-4 alkyl, J--CO.sub.2 R', CONR', SR', NR'R", C .sub.1-4 alkoxy, hydroxy, CN, CF.sub.3, halo, or ##STR2## with the proviso that at least one R.sup.2 is J--CO.sub.2 R; and J is a single bond, --OCR'.sub.2 --, --NR'CR'.sub.2 --, CR'.sub.2 --CR'.sub.2 --, --CR'.sub.2 --, --CR'.dbd.CR', or --C(O)NR'CR'.sub.2 --;each R.sup.14 independently is C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-4 alkyl, Ar-C.sub.0-4 alkyl, C(O)R', CN, NO.sub.2, SO.sub.2 R', or C(O)OR.sup.15 ;or a pharmaceutically acceptable salt thereof, are effective for inhibiting platelet aggregation.

    摘要翻译: 式(I)的化合物:W-Z-(CR'R10)r-U-(CR'2)s-V-A(I)其中:A是W是+ E,crc N + EE; Z是(CH 2)1-2; U和V独立地作为CO,CR'2,C(= CR'2),S(O)r,O,NR',CR'OR',CR'(OR“)CR'2,CR' (OR),C(O)CR'2,CR'2C(O),CONR',NR'CO,OC(O),C(O)O,C(O) ),C(S)NR',NR'C(S),S(O)rNR',NR'S(O)r,N = N,NR'NR',NR'CR'2,NR'CR'2, CR'2O,OCR'2,C 3BOND C,CR'= CR'或CR'(NR'R“)C(O); 每个r独立为0至3; s为0〜2; 每个R'独立地为H,C 1-4烷基,C 3-7环烷基-C 0-4烷基或Ar-C 0-4烷基; 每个R“独立地是R',-C(O)R'或-C(O)OR 15; R 10是H,C 1-4烷基或-NR'R'; 每个R 15独立地为C 1-4烷基,C 3-7环烷基-C 0-4烷基或Ar-C 0-4烷基; R 2存在一次或两次作为C 1-4烷基,J-CO 2 R',CONR',SR',NR'R“,C 1-4烷氧基,羟基,CN,CF 3,卤素,或条件是至少一个R 2 是J-CO2R; 并且J是单键,-OCR'2 - ,-NR'CR'2 - ,CR'2-CR'2,-CR'2-,-CR'= CR'或-C(O)NR 'CR'2-; 每个R 14独立地是C 1-4烷基,C 3-7环烷基-C 0-4烷基,Ar-C 0-4烷基,C(O)R',CN,NO 2,SO 2 R'或C(O)OR 15; 或其药学上可接受的盐对抑制血小板聚集是有效的。

    Platelet aggregation inhibiting compounds
    10.
    发明授权
    Platelet aggregation inhibiting compounds 失效
    血小板聚集抑制化合物

    公开(公告)号:US5726192A

    公开(公告)日:1998-03-10

    申请号:US464728

    申请日:1995-08-08

    摘要: This invention relates to compounds of the formula: W--Z--(CR'R.sup.10).sub.r --U--(CR'.sub.2).sub.s --V--A wherein: ##STR1## A is W is R'R"N--; Z is Het; U and V independently are absent or present as CO, CR'.sub.2, C(.dbd.CR'.sub.2), S(O).sub.r, O, NR', CR'OR', CR'(OR")CR'.sub.2, CR'.sub.2 CR'(OR"), C(O)CR'.sub.2, CR'.sub.2 C(O), CONR', NR'CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR', NR'C(S), S(O).sub.r NR', NR'S(O).sub.r, N.dbd.N, NR'NR', NR'CR'.sub.2, NR'CR'.sub.2, CR'.sub.2 O, OCR'.sub.2, .sup.c.tbd.c, CR'.dbd.CR', or CR'(NR'R")C(O); each r independently is 0 to 3; s is 0 to 2; each R' independently is H, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-4 alkyl, or Ar--C.sub.0-4 alkyl; each R" independently is R', --C(O)R', or --C(O)OR.sup.15 ; R.sup.10 is as H, C.sub.1-4 alkyl, or --NR'R'; each R.sup.15 independently is C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-4 alkyl, or AR--C.sub.0-4 alkyl; R.sup.2 is present once or twice as C.sub.1-4 alkyl, J--CO.sub.2 R', CONR', SR', NR'R", C.sub.1-4 alkoxy, hydroxy, CN, CF.sub.3, halo, or ##STR2## with the proviso that at least one R.sup.2 is J--CO.sub.2 R; J is a single bond, --OCR'.sub.2 --, --NR'CR'.sub.2 --, CR'.sub.2 --CR'.sub.2 --, --CR'.sub.2 --, --CR'.dbd.CR', or --C(O)NR'CR'.sub.2 --; and each R.sup.14 independently is C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-4 alkyl, Ar--C.sub.0-4 alkyl, C(O)R', CN, NO.sub.2, SO.sub.2 R', or C(O)OR.sup.15 ; or a pharmaceutically acceptable salt thereof.

    摘要翻译: PCT No.PCT / US93 / 12530 Sec。 371日期:1995年8月8日 102(e)日期1995年8月8日PCT提交1993年12月22日PCT公布。 第WO94 / 14775号​​公报 日期:1994年7月7日本发明涉及下式的化合物:WZ-(CR'R10)rU-(CR'2)sV-A其中:不存在或作为CO,CR'2,C(= CR'2),S(O)r,O,NR',CR'OR',CR'(OR“)CR'2,CR'2CR'(OR”),C(O)CR'2, CR(O),CONR',NR'CO,OC(O),C(O)O,C(S)O,OC(S),C(S)NR',NR'C(S) S(O)rNR',NR'(O)r,N = N,NR'NR',NR'CR'2,NR'CR'2,CR'2O,OCR'2,c 3BOND c,CR'= CR '或CR'(NR'R“)C(O); 每个r独立为0至3; s为0〜2; 每个R'独立地为H,C 1-4烷基,C 3-7环烷基-C 0-4烷基或Ar-C 0-4烷基; 每个R“独立地是R',-C(O)R'或-C(O)OR 15; R 10为H,C 1-4烷基或-NR'R'; 每个R 15独立地为C 1-4烷基,C 3-7环烷基-C 0-4烷基或AR-C 0-4烷基; R2存在一次或两次作为C 1-4烷基,J-CO 2 R',CONR',SR',NR'R“,C 1-4烷氧基,羟基,CN,CF 3,卤素或”IMAGE“,条件是至少 一个R2是J-CO2R; J是单键,-OCR'2-,-NR'CR'2-,CR'2-CR'2-,-CR'2-,-CR'= CR'或-C(O)NR' CR'2-; 并且每个R 14独立地为C 1-4烷基,C 3-7环烷基-C 0-4烷基,Ar-C 0-4烷基,C(O)R',CN,NO 2,SO 2 R'或C(O)OR 15; 或其药学上可接受的盐。